Richard Ranieri Biography and Net Worth

Director of Xencor

Richard J. Ranieri joined our Board in December 2017. Mr. Ranieri has more than 40 years of senior level biopharmaceutical human resource experience. He has served as a senior advisor to BioMarin Pharmaceutical Inc. (“BioMarin”) since January 2019, and from September 2013 through December 2018, he served as executive vice president of human resources and corporate affairs at BioMarin. Previously Mr. Ranieri served as executive vice president, human resources at Dendreon Pharmaceuticals from 2010 to 2013, and as executive vice president, human resources and administration at Sepracor, Inc. from 2008 to 2010. Earlier in his career, Mr. Ranieri served in executive positions at Neurocrine, Genencor International, and SmithKline Beecham. He received a B.A. in social science and accounting from Villanova University, and an M.A. in organizational development from Rider University. We believe that Mr. Ranieri’s leadership experience in human resources with biotechnology organizations qualifies him to serve on our Board.

What is Richard J. Ranieri's net worth?: The estimated net worth of Richard J. Ranieri is at least $347.98 thousand as of June 16th, 2025. Mr. Ranieri owns 19,183 shares of Xencor stock worth more than $347,980 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Ranieri may own. Learn More about Richard J. Ranieri's net worth.
How do I contact Richard J. Ranieri?: The corporate mailing address for Mr. Ranieri and other Xencor executives is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. Xencor can also be reached via phone at (626) 305-5900 and via email at [email protected]. Learn More on Richard J. Ranieri's contact information.
Has Richard J. Ranieri been buying or selling shares of Xencor?: Richard J. Ranieri has not been actively trading shares of Xencor during the last quarter. Most recently, Richard J. Ranieri sold 2,993 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a transaction totalling $27,595.46. Following the completion of the sale, the director now directly owns 19,183 shares of the company's stock, valued at $176,867.26. Learn More on Richard J. Ranieri's trading history.
Who are Xencor's active insiders?: Xencor's insider roster includes Bassil Dahiyat (CEO), John Desjarlais (Executive Vice President, Research & Chief Scientific Officer), Celia Eckert (Senior Vice President, General Counsel and Corporate Secretary), Ellen Feigal (Director), Kurt Gustafson (Director), Alan Montgomery (Director), Richard Ranieri (Director), Nancy Valente (Executive Vice President & Chief Development Officer), and Allen Yang (CMO). Learn More on Xencor's active insiders.
Are insiders buying or selling shares of Xencor?: In the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 15,810 shares worth more than $154,123.16. The most recent insider tranaction occured on June, 16th when Director Alan Bruce Montgomery sold 2,215 shares worth more than $20,422.30. Insiders at Xencor own 4.8% of the company. Learn More about insider trades at Xencor.
Information on this page was last updated on 6/16/2025.

Richard J. Ranieri Insider Trading History at Xencor

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/16/2025	Sell	2,993	$9.22	$27,595.46	19,183

Richard J. Ranieri Buying and Selling Activity at Xencor

Xencor Company Overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Today's Range

Now: $18.14

$17.02

$18.68

50 Day Range

MA: $14.36

$11.55

$18.14

2 Week Range

Now: $18.14

$6.92

$26.59

Volume

950,883 shs

Average Volume

728,373 shs

Market Capitalization

$1.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96